Risks of tuberculosis, meningitis, candidiasis and fungal infections in patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data
British Journal of Dermatology · 15.09.2026
DOI: 10.1093/bjd/ljag397 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift British Journal of Dermatology, online erschienen am 15.09.2026. Verfasst von Heber Rew Bright Bright und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Association of Dermatologists, BADBIR, Psoriasis Association.
Abstract (Originalsprache)
Background
Systemic treatments for psoriasis confer differential risk profiles for infections such as tuberculosis (TB), meningitis, candidiasis and other fungal infections. However, real-world comparative data including interleukin (IL)-17 and IL-23 inhibitors remain limited.
Methods
We conducted a nationwide cohort study using data from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) from 2007 to 2024. Adults with psoriasis receiving systemic treatments were included and followed from treatment initiation until treatment discontinuation, death or last available follow-up data. Primary outcomes included TB, meningitis, candidiasis and other fungal infections. Incidence rates per 1000 person-years (PY) were calculated and incidence rate ratios (IRRs) were estimated using a doubly robust interval-based Poisson regression model. An entropy balancing method was used to achieve covariate balance across treatment groups and multiple imputation was used to handle missing baseline data.
Results
A total of 40 930 treatment episodes from 18 635 patients contributing 118 018 PY of follow-up were included in this analysis. During the follow-up, 22 TB cases, 29 meningitis cases and 888 fungal infection cases, including 450 cases of candidiasis, were reported. The overall incidence rates were 0.18 [95% confidence interval (CI) 0.12–0.28] for TB, 0.25 (95% CI 0.16–0.35) for meningitis and 7.53 (95% CI 7.05–8.05) for fungal infections per 1000 PY. Most TB and meningitis cases were associated with tumour necrosis factor-α inhibitors, particularly adalimumab. Meningitis was predominantly viral and TB was largely pulmonary. Thirty-day mortality was seen in < 5 cases in meningitis. IL-17 inhibitors alone exhibited an increased risk of candidiasis compared with all other systemic treatment groups, with IRRs ranging from 2.67 (95% CI 1.33–5.36) vs. apremilast to 4.65 (95% CI 3.46–6.24) vs. the IL-12/23 inhibitor. Individual IL-17 inhibitors did not exhibit significant differences in the risk of candidiasis. With fungal infections other than candidiasis, no statistically significant differences were observed between treatment groups.
Conclusions
In this large cohort study, TB and meningitis were rare and longer-term follow-up is required to further characterize the risk with newer treatments. Candidiasis and fungal infections were more common with increased risks in patients receiving IL-17 inhibitors.
Autor:innen und Institutionen
- Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, Universit…
- St John's Institute of Dermatology, King's College London and Guy's and St Thomas' NHS Foundation Trust, London, UK.
- University of Leeds, Chapel Allerton Hospital, Leeds, UK.
- Institute of Translational and Clinical Medicine, Newcastle University and NIHR Biomedical Research Centre, Newcastle upon Tyne, UK.
- Division of Musculoskeletal and Dermatological Sciences, University of Manchester, Manchester, UK.
ORCID-Profile: Heber Rew Bright Bright, Philip Laws, Richard B Warren, Zenas Z N Yiu
Förderung
- British Association of Dermatologists
- BADBIR
- Psoriasis Association
- National Institute for Health and Care Research
- NIHR
- Manchester Biomedical Research Centre
- NIHR Newcastle Biomedical Research Centre
- NIHR Newcastle Patient Safety Research Centre
Zitieren
APA
Bright, H. R. B., Smith, C. H., Laws, P., Reynolds, N. J., Phan, D. B., Lunt, M., Warren, R. B., & Yiu, Z. Z. N. (2026). Risks of tuberculosis, meningitis, candidiasis and fungal infections in patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag397
Vancouver
Bright HRB, Smith CH, Laws P, Reynolds NJ, Phan DB, Lunt M, et al. Risks of tuberculosis, meningitis, candidiasis and fungal infections in patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag397
BibTeX
@article{Bright2026,
author = {Bright, Heber Rew Bright and Smith, Catherine H and Laws, Philip and Reynolds, Nick J and Phan, Duc Binh and Lunt, Mark and Warren, Richard B and Yiu, Zenas Z N},
title = {Risks of tuberculosis, meningitis, candidiasis and fungal infections in patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data},
journal = {British Journal of Dermatology},
year = {2026},
doi = {10.1093/bjd/ljag397}
}
EUVIMED